{"organizations": [], "uuid": "6eeecf71d2e59b21d37a8745f55a7f2d12236807", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180403.html", "section_title": "Archive News &amp; Video for Tuesday, 03 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/idUSFWN1RG0F2", "country": "US", "domain_rank": 408, "title": "REFILE-BRIEF-Rigel Announces Topline Data From Phase 2 Study Of Fostamatinib", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.774, "site_type": "news", "published": "2018-04-03T19:11:00.000+03:00", "replies_count": 0, "uuid": "6eeecf71d2e59b21d37a8745f55a7f2d12236807"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/idUSFWN1RG0F2", "ord_in_thread": 0, "title": "REFILE-BRIEF-Rigel Announces Topline Data From Phase 2 Study Of Fostamatinib", "locations": [], "entities": {"persons": [{"name": "fostamatinib", "sentiment": "none"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "rigel pharmaceuticals inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "(Refiles to correct formatting of bullets)\nApril 3 (Reuters) - Rigel Pharmaceuticals Inc:\n* RIGEL ANNOUNCES TOPLINE DATA FROM PROOF-OF-CONCEPT PHASE 2 STUDY OF FOSTAMATINIB IN IGA NEPHROPATHY\n* TRIAL DID NOT ACHIEVE STATISTICAL SIGNIFICANCE FOR ITS PRIMARY ENDPOINT\n* ‍FOSTAMATINIB WAS WELL TOLERATED WITH MOSTLY MILD TO MODERATE ADVERSE EVENTS​\n* FURTHER ANALYSIS OF THE TREATMENT, INCLUDING HISTOLOGY, ARE EXPECTED LATER IN YEAR\n* ‍THERE WERE NO NEW SAFETY SIGNALS COMPARED TO FOSTAMATINIB’S SAFETY DATABASE ACROSS ALL INDICATIONS​\n* PATIENTS WITH GREATER THAN 1 GRAM/DAY OF PROTEINURIA HAVE AN INCREASED RISK OF DISEASE PROGRESSION AND REPRESENT AN UNMET MEDICAL NEED\n* ‍RIGEL PLANS TO SEEK A PHARMACEUTICAL PARTNER TO COLLABORATE IN CONDUCT OF FOLLOW-ON CLINICAL STUDIES IN IGAN​\n* PHARMACEUTICAL​ PARTNER WOULD TAKE RESPONSIBILITY FOR SUBSEQUENT COMMERCIALIZATION OF FOSTAMATINIB IF IN AN EX-U.S. TERRITORY Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-03T19:11:00.000+03:00", "crawled": "2018-04-04T12:15:51.046+03:00", "highlightTitle": ""}